Hit Tumors* Hard With TheraSphere
TheraSphere receives FDA Approval!
After 20 years as a humanitarian exemption device (HDE), the FDA grants TheraSphere pre-market approval, making TheraSphere the only Y-90 therapy indicated for HCC. The FDA has also granted Breakthrough Device designation for TheraSphere treatment for patients with glioblastoma.*
*TheraSphere has not been approved for treatment of patients with glioblastoma
The TARGET Study
The TARGET Study is a global, real-world data set across 8 countries demonstrating the reproducibility of treatment with TheraSphere Y-90 glass microspheres, confirmed by Simplicit90Y™ Personalized Dosimetry Software.Learn More
Your patients are fighting for more than their survival. They’re fighting for their quality of life. TheraSphere is uniquely able to help you strike first on both fronts.
Glass Matters With Y-90
1. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.
*Refers to HCC or associated tumors